Epicor Puts AI-Enabled Insights to Work for the Make, Move, and Sell Economy
LAS VEGAS–(BUSINESS WIRE)–Epicor, a global leader of industry-specific enterprise software to promote business growth, will…
News
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice…
Notice of Extraordinary General Meeting of Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586, with its registered office in Stockholm, gives notice…
IBT resolves on a rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN…
IBT resolves on a rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN…
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Company on track to complete planned interim analyses from two ongoing Phase 2 studies of…
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Company on track to complete planned interim analyses from two ongoing Phase 2 studies of…
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 Erick Lucera Editas Medicine today…
Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer
Michelle Robertson to remain with Company until August 16, 2023 Erick Lucera Editas Medicine today…
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 16, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Bioventus Reports First Quarter Financial Results
DURHAM, N.C., May 16, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the…
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical…
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
CARSON CITY, Nev., May 16, 2023 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
Call scheduled for Thursday, June 22nd at 4:30 pm Eastern Time GARDEN CITY, N.Y., May…
Beyond Air® Schedules Fiscal Year End 2023 Financial Results Conference Call and Webcast
Call scheduled for Thursday, June 22nd at 4:30 pm Eastern Time GARDEN CITY, N.Y., May…
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75%…
X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75%…
Mydecine Reports Financial Results for the First Quarter of Fiscal Year 2023
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC:…